XML 130 R112.htm IDEA: XBRL DOCUMENT
v3.25.1

Commitments and Contingent Liabilities - Litigation and Claims Involving Distribution of Controlled Substances (Narrative) (Details) $ in Millions |  |  | 12 Months Ended |  |
--- | --- | --- | --- | --- | ---
Nov. 12, 2024 USD ($) | Feb. 25, 2019 | Mar. 31, 2025 USD ($) case jurisdiction state distributor | Mar. 31, 2024 USD ($) | Mar. 31, 2023 USD ($) | Feb. 12, 2025 USD ($) | Nov. 27, 2024 USD ($)
Loss Contingencies [Line Items] |  |  |  |  |  |  |
Litigation settlement charges |  |  | $ 108 | $ 147 | $ (8) |  |
National Prescription Opiate Litigation |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |
Number of jurisdictions that did not participate in settlement | jurisdiction |  |  | 1 |  |  |  |
Litigation settlement charges |  |  | $ 114 | 149 |  |  |
National Prescription Opiate Litigation | Corporate Segment And U.S. Pharmaceutical Segment |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |
Litigation settlement charges |  |  | $ 57 |  |  |  |
National Prescription Opiate Litigation | Corporate |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |
Litigation settlement charges |  |  |  | 75 |  |  |
National Prescription Opiate Litigation | U.S. Pharmaceutical |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |
Litigation settlement charges |  |  |  | 74 |  |  |
Canada | National Prescription Opiate Litigation |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |
Number of complaints served | case |  |  | 4 |  |  |  |
Individual Claimant | Canada | National Prescription Opiate Litigation |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |
Number of complaints served | case |  |  | 1 |  |  |  |
National Prescription Opiate Litigation |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |
Number of other defendants | distributor |  |  | 2 |  |  |  |
Number of states | state |  |  | 48 |  |  |  |
Loss contingency, number of cases dismissed | case |  |  | 2,300 |  |  |  |
Litigation settlement, award amount to be used by state and local government |  |  | 85.00% |  |  |  |
Amounts awarded to plaintiff | $ 192 |  |  |  |  |  |
Restricted cash |  |  |  |  |  | $ 114 | $ 149
National Prescription Opiate Litigation | State of Alabama and Subdivisions |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |
Payments for legal settlements |  |  | $ 75 |  |  |  |
Aggregate amount expected to be paid |  |  | 99 |  |  |  |
National Prescription Opiate Litigation | Settling Governmental Entities and Cherokee Nation | Settled Litigation |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |
Payments for legal settlements |  |  | $ 515 | $ 544 | $ 1,100 |  |
National Prescription Opiate Litigation | Native American Tribes Other Than Cherokee Nation |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |
Percentage of total settlement to be used to remediate damages (in percent) |  |  | 0.85 |  |  |  |
National Prescription Opiate Litigation | Three Largest U.S. Pharmaceutical Distributors |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |
Payments for legal settlements |  |  | $ 2,000 |  |  |  |
Aggregate amount expected to be paid |  |  | 5,900 |  |  |  |
National Prescription Opiate Litigation | Three National Pharmaceutical Distributors | State of West Virginia and Subdivisions |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |
Payments for legal settlements |  |  | 68 |  |  |  |
National Prescription Opiate Litigation | Three National Pharmaceutical Distributors | State of West Virginia and Subdivisions | Settled Litigation |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |
Aggregate amount expected to be paid |  |  | 84 |  |  |  |
National Prescription Opiate Litigation | Three National Pharmaceutical Distributors | Cherokee Nation |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |
Payments for legal settlements |  |  | 112 |  |  |  |
Aggregate amount expected to be paid |  |  | $ 84 |  |  |  |
United States ex rel. Manchester v. Purdue Pharma, L.P., et al |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |
Period within which party can be substituted |  | 90 days |  |  |  |  |

X
- Definition Litigation Settlement, Amount Awarded to Other Party, Percentage of Total Settlement to Be Used to Remediate Damages + References No definition available. + Details
Name: | mck_LitigationSettlementAmountAwardedToOtherPartyPercentageOfTotalSettlementToBeUsedToRemediateDamages
Namespace Prefix: | mck_
Data Type: | xbrli:pureItemType
Balance Type: | na
Period Type: | instant

X
- Definition Litigation Settlement, Award Amount To Be Used by State and Local Government + References No definition available. + Details
Name: | mck_LitigationSettlementAwardAmountToBeUsedByStateAndLocalGovernment
Namespace Prefix: | mck_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Loss Contingency, Claims Settled, Number Of Jurisdictions Not Participating In Settlement + References No definition available. + Details
Name: | mck_LossContingencyClaimsSettledNumberOfJurisdictionsNotParticipatingInSettlement
Namespace Prefix: | mck_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Loss Contingency, Number Of Cases Dismissed + References No definition available. + Details
Name: | mck_LossContingencyNumberOfCasesDismissed
Namespace Prefix: | mck_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Loss Contingency, Number of Other Defendants + References No definition available. + Details
Name: | mck_LossContingencyNumberOfOtherDefendants
Namespace Prefix: | mck_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Loss Contingency, Number of States + References No definition available. + Details
Name: | mck_LossContingencyNumberofStates
Namespace Prefix: | mck_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Loss Contingency, Party Substitution Period to Prevent Case Dismissal + References No definition available. + Details
Name: | mck_LossContingencyPartySubstitutionPeriodtoPreventCaseDismissal
Namespace Prefix: | mck_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 + Details
Name: | us-gaap_GainLossRelatedToLitigationSettlement
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount awarded to other party in judgment or settlement of litigation. + References No definition available. + Details
Name: | us-gaap_LitigationSettlementAmountAwardedToOtherParty
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 720 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 27 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 + Details
Name: | us-gaap_LossContingenciesLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of damages awarded to the plaintiff in the legal matter. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9 + Details
Name: | us-gaap_LossContingencyDamagesAwardedValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of pending claims pertaining to a loss contingency. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9 + Details
Name: | us-gaap_LossContingencyPendingClaimsNumber
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition The amount of cash paid for the settlement of litigation or for other legal issues during the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (g) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details
Name: | us-gaap_PaymentsForLegalSettlements
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details
Name: | us-gaap_RestrictedCash
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Details
Name: | us-gaap_LossContingenciesByNatureOfContingencyAxis=mck_NationalPrescriptionOpiateLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=mck_CorporateSegmentAndU.S.PharmaceuticalSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=mck_USPharmaceuticalSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_CA
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=mck_IndividualClaimantMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=mck_NationalPrescriptionOpiateLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=mck_StateOfAlabamaAndSubdivisionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=mck_SettlingGovernmentalEntitiesAndCherokeeNationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=mck_NativeAmericanTribesOtherThanCherokeeNationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=mck_ThreeLargestUSPharmaceuticalDistributorsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=mck_ThreeNationalPharmaceuticalDistributorsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=mck_StateOfWestVirginiaAndSubdivisionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=mck_CherokeeNationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=mck_UnitedStatesexrel.Manchesterv.PurduePharmaL.P.etalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |